BC Innovations | Feb 10, 2011
Tools & Techniques

Models for QT prolongation

A group at the Technion Israel Institute of Technology and a team at the Stanford University School of Medicine have independently developed human stem cell-based models of long QT syndrome, 1,2 a potentially fatal cardiac...
BC Week In Review | Oct 22, 2007
Clinical News

MEM 1003: Phase IIa data

In a double-blind, U.S. Phase IIa trial in 183 patients, MEM 1003 missed the primary endpoint of a significant improvement in ADAS-cog score vs. placebo after 12 weeks. The company said there was a high...
BioCentury | Oct 22, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/19 cls Biogen Idec (BIIB) Baird Christopher Raymond Other Neutral 16% $80.22 Jefferies Adam Walsh Price target Hold Raymond raised...
BC Extra | Oct 16, 2007
Clinical News

Memory off after AD data

MEMY fell $0.69 (39%) to $1.06 on Monday after MEM 1003 missed the primary endpoint of a significant improvement in Alzheimer's Disease Assessment Scale--Cognitive subscale (ADAS-cog) score vs. placebo after 12 weeks in a Phase...
BC Week In Review | Apr 9, 2007
Clinical News

MEM 1003: Completed Phase IIa enrollment

MEMY completed enrollment in a double-blind, U.S. Phase IIa trial in 180 patients. The trial will compare 30 or 90 mg of twice-daily MEM 1003 to placebo after 12 weeks. Patients will then be evaluated...
BC Week In Review | Mar 12, 2007
Clinical News

MEM 1003: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial in 84 patients, MEM 1003 missed all primary and secondary endpoints. MEMY said 26% of patients receiving MEM 1003 showed a 50% improvement from baseline in YMRS vs....
BC Extra | Mar 6, 2007
Clinical News

Memory falls on acute mania data

MEMY fell $1.12 (36%) to $2.01 on 1.7 million shares on Monday after MEM 1003 missed the primary and secondary endpoints in a Phase IIa trial to treat acute mania in bipolar disorder. In the...
BC Week In Review | Mar 5, 2007
Company News

Memory Pharmaceuticals, The Stanley Medical Research Institute deal

MEMY received a $640,000 milestone from the institute in January under a 2006 deal to develop MEMY's MEM 1003 to treat acute mania in bipolar disorder. The payment was triggered by MEMY meeting a set...
BioCentury | Feb 26, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/23 cls Aradigm (ARDM) Merriman Curhan Ford E. Russell McAllister New Buy 13% $1.46 McAllister set a $4-$5 fair value...
BioCentury | Jan 22, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk cls 1/19 cls Actelion (SWX:ATLN) ING Bank Mark Clark New Sell 6% CHF273.5 Lehman Peter Welford Price target Overweight Clark set a CHF220 target. He...
Items per page:
1 - 10 of 36